Иностранные статьи

Logo1

Zhestovskaja AS, Kukes VG, Sychev DA. Personalized medicine: myth or reality? The position of Russian clinical pharmacologists. EPMA J.2013;4(1):13.
Zastrozhin MS., Sorokin AS., Agibalova AV., et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers Human Psychopharmacology: Clinical and Experimental.2018;e2677, 8.
Zastrozhin MS, Smirnov VV, Sychev DA, et al. CYP3A4 activity and haloperidol effects in alcohol addicts. Int J Risk Saf Med. 2015;27:23-4.
Zastrozhin MS, Skryabin VY, Miroshkin SS, et al. Pharmacogenetics of alcohol addiction: current perspectives. The Application of Clinical Genetics 2019, 12:131-140
Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and Personalized Medicine 2018,11:1—5.
Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;113—119.
Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Oct
Zastrozhin M, Skryabin V, Smirnov V, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 May 17.
Zagorodnikova Goryachkina K, Burbello A, Sychev D, et al. Clinical pharmacology in Russia-historical development and current state. Eur J Clin Pharmacol. 2015;71(2):159-63.
Sychev DA, Zastrozhin MS, Smirnov VV, et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmgenomics Pers Med. 2016;9:89–95.
Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54.
Sychev DA, Shuev GN, Chertovskih JV, et al. The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med. 2016;9:59–63.
Sychev DA, Rozhkov AV, Kazakov RE, et al. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. Drug Metab Pers Ther. 2016;31(3):173-8.
Sychev DA, Rozhkov AV, Ananichuk AV et al. Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. Drug Metabol Pers Ther 2017; aop.
Sychev DA, Malova EU. Evidence-based pharmacogenetics: Is it possible? Int J Risk Saf Med. 2015;27:97-98.
Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty Pharmacogenomics and Personalized Me
Sychev DA, Baturina OA, Mirzaev KB, et al. CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban Pharmacogenomics and Personalized Medicine Volume 2020:13 Pages 29—37
Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy. 2018:12;1147—1156.
Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Mar 8. doi: 10.1007/s11033-019-04722-w.
Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine 2018, 11:157-165.

Страница 1 из 2

Zhestovskaja AS, Kukes VG, Sychev DA. Personalized medicine: myth or reality? The position of Russian clinical pharmacologists. EPMA J.2013;4(1):13.

Zastrozhin MS., Sorokin AS., Agibalova AV., et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers Human Psychopharmacology: Clinical and Experimental.2018;e2677, 8.

Zastrozhin MS, Smirnov VV, Sychev DA, et al. CYP3A4 activity and haloperidol effects in alcohol addicts. Int J Risk Saf Med. 2015;27:23-4.

Zastrozhin MS, Skryabin VY, Miroshkin SS, et al. Pharmacogenetics of alcohol addiction: current perspectives. The Application of Clinical Genetics 2019, 12:131-140

Zastrozhin MS, Grishina EA, Ryzhikova KA, et al. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. Pharmacogenomics and Personalized Medicine 2018,11:1—5.

Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;113—119.

Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Oct

Zastrozhin M, Skryabin V, Smirnov V, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Can J Physiol Pharmacol. 2019 May 17.

Zagorodnikova Goryachkina K, Burbello A, Sychev D, et al. Clinical pharmacology in Russia-historical development and current state. Eur J Clin Pharmacol. 2015;71(2):159-63.

Sychev DA, Zastrozhin MS, Smirnov VV, et al. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmgenomics Pers Med. 2016;9:89–95.

Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genet Test Mol Biomarkers. 2018 Jan;22(1):51-54.

Sychev DA, Shuev GN, Chertovskih JV, et al. The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med. 2016;9:59–63.

Sychev DA, Rozhkov AV, Kazakov RE, et al. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. Drug Metab Pers Ther. 2016;31(3):173-8.

Sychev DA, Rozhkov AV, Ananichuk AV et al. Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. Drug Metabol Pers Ther 2017; aop.

Sychev DA, Malova EU. Evidence-based pharmacogenetics: Is it possible? Int J Risk Saf Med. 2015;27:97-98.

Sychev DA, Levanov AN, Shelekhova TV, et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty Pharmacogenomics and Personalized Me

Sychev DA, Baturina OA, Mirzaev KB, et al. CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban Pharmacogenomics and Personalized Medicine Volume 2020:13 Pages 29—37

Sychev DA, Ashraf GM, Svistunov AA, et al. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Design, Development and Therapy. 2018:12;1147—1156.

Sychev DA, Abdullaev SP, Mirzaev KB, et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep. 2019 Mar 8. doi: 10.1007/s11033-019-04722-w.

Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine 2018, 11:157-165.

Популярные теги

Последние изменения

Наши Партнеры

Вход